SCHEMBL559282

SCHEMBL559282

NC1CCC(Nc2ncc3cccc(OC4CCOC4)c3n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK7 P50613 5/20 0.44
CDK9 P50750 5/20 0.44
JAK2 O60674 2/20 0.41
JAK1 P23458 2/20 0.41
TYK2 P29597 2/20 0.41
JAK3 P52333 2/20 0.41
MAPK10 P53779 3/20 0.39
JUN P05412 1/20 0.39
TNIK Q9UKE5 1/20 0.39
MAPK8 P45983 4/20 0.38
TTK P33981 1/20 0.38
MAPK9 P45984 2/20 0.38
MCHR1 Q99705 1/20 0.38
MAPK14 Q16539 2/20 0.36
MAPK6 Q16659 1/20 0.36
EGFR P00533 2/20 0.36
ITK Q08881 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL559281 1.00 CDK7 (0.44) CDK7CDK9JAK2JAK1TYK2
SCHEMBL559884 0.94 CDK7 (0.45) CDK7CDK9JAK2JAK1TYK2
SCHEMBL559883 0.94 CDK7 (0.45) CDK7CDK9JAK2JAK1TYK2
SCHEMBL558775 0.91 JAK2 (0.43) JAK2JAK1TYK2JAK3MAPK10
SCHEMBL559669 0.90 MAPK10 (0.51) JAK2JAK1TYK2JAK3MAPK10
SCHEMBL558597 0.90 MAPK10 (0.51) JAK2JAK1TYK2JAK3MAPK10
SCHEMBL559307 0.90 MAPK10 (0.51) JAK2JAK1TYK2JAK3MAPK10
SCHEMBL558596 0.90 MAPK10 (0.51) JAK2JAK1TYK2JAK3MAPK10
SCHEMBL559308 0.90 MAPK10 (0.51) JAK2JAK1TYK2JAK3MAPK10
SCHEMBL559670 0.90 MAPK10 (0.51) JAK2JAK1TYK2JAK3MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035194-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 2012-02-09 US disclosed
US-7998978-B2 Substituted 2-amino-fused heterocyclic compounds PFIZER INC. (US) 2011-08-16 US disclosed
US-20100056506-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035194-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS MAPK1, SLC5A1, ATF1 CDK7 660/4885CDK9 1141/4885JAK2 54/4885
US-20100056506-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS MAPK1, SLC5A1, ATF1 CDK7 660/4885CDK9 1141/4885JAK2 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.